← Back to Search

Unknown

GDC-6599 for Chronic Cough

Phase 2
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Never or former smoker (≥ 6 months prior to screening) with < 20 pack-years or equivalent history
Physician diagnosis of asthma for ≥ 12 months based upon GINA STEP 2-5
Must not have
Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the final dose of GDC-6599
Treatment with any strong inhibitor or inducer of CYP3A within 28 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to day 14

Summary

This trial is testing a new drug called GDC-6599 to see if it can help people with chronic coughs that haven't been cured by other treatments. The study will look at how well the drug works, its safety, and how it behaves in the body.

Who is the study for?
Adults with chronic cough and a physician's diagnosis of asthma or COPD, who are not current smokers and have used bronchodilator medication for at least 12 weeks. They must not be pregnant, breastfeeding, or planning to become pregnant soon. Participants should not have had respiratory infections recently or been treated with certain medications like opioids for cough within the last two weeks.
What is being tested?
The trial is testing GDC-6599 against a placebo to see if it helps people with chronic cough. It's a Phase IIa study where patients will randomly receive either the drug or placebo in different periods without knowing which one they're taking (double-blind). The effects on coughing, safety, how the body processes the drug (pharmacokinetics), and its biological actions (pharmacodynamics) are being studied.
What are the potential side effects?
While specific side effects of GDC-6599 aren't listed here, common ones in trials may include nausea, headache, dizziness, fatigue or allergic reactions. Safety monitoring will identify any potential adverse effects during this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never smoked or quit smoking more than 6 months ago, with less than 20 pack-years of history.
Select...
I have been diagnosed with asthma for at least a year.
Select...
I've had a chest X-ray or CT scan in the last 6 months showing no serious lung issues other than COPD.
Select...
My cough is severe, scoring 40 or more on a scale.
Select...
I have been on stable lung medication for at least 12 weeks.
Select...
I have been diagnosed with mild to moderate COPD.
Select...
I have been on stable asthma treatment for at least 3 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant soon.
Select...
I haven't taken strong CYP3A affecting drugs in the last month.
Select...
I have not taken cough suppressant medication in the last 2 weeks.
Select...
I have had issues with food or liquid going into my lungs or repeated lung infections.
Select...
I have not had a respiratory infection in the last 8 weeks.
Select...
I haven't taken opioids or specific medications for cough in the last 2 weeks.
Select...
I have a history of bleeding or bruising easily.
Select...
I haven't had cancer in the last 5 years, except for certain skin or cervical cancers.
Select...
I have had serious liver problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in cough frequency per hour, assessed objectively over 24 hours (24-hour OCC) using VitaloJAK cough recorder
Secondary study objectives
Change in cough hypersensitivity to mannitol, measured as the CDR to mannitol
Change in mannitol-induced AHR
Change in the severity of cough, as assessed through the use of the patient-reported cough severity NRS score
+1 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease with Chronic BronchitisExperimental Treatment3 Interventions
Patients with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
Group II: Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary DiseaseExperimental Treatment3 Interventions
Patients with Chronic Obstructive Pulmonary Disease will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5.
Group III: Part A: Unexplained Chronic CoughExperimental Treatment3 Interventions
Patients with Unexplained Chronic Cough will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
Group IV: Part A: CRC Asthma non-atopicExperimental Treatment3 Interventions
Patients with CRC non-atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
Group V: Part A: CRC Asthma atopicExperimental Treatment3 Interventions
Patients with CRC atopic asthma will be randomized in a 1:1 ratio to receive GDC-6599 or placebo for 14 days during the first study period (Treatment Period 1, Study Visits 2-4). Following a 14-day washout period, patients will cross over to the second study period (Treatment Period 2, Study Visits 5-7) and will receive the alternate treatment (GDC-6599 or placebo) for 14 days starting at Study Visit 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GDC-6599
2023
Completed Phase 2
~80
Mannitol
2019
Completed Phase 4
~2900

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Chronic Obstructive Pulmonary Disease (COPD) include bronchodilators, inhaled corticosteroids, and mucolytics. Bronchodilators, such as beta agonists and muscarinic antagonists, relax the muscles around the airways, improving airflow. Inhaled corticosteroids reduce airway inflammation, decreasing swelling and mucus production. Mucolytics thin and loosen mucus, aiding in its clearance from the airways. These mechanisms are vital for COPD patients as they alleviate symptoms, enhance breathing, and reduce the frequency of exacerbations, thereby improving overall quality of life.
Long-Acting Bronchodilator Use in the Management of Stable COPD.Should mild COPD be treated? Evidence for early pharmacological intervention.A self-management approach using self-initiated action plans for symptoms with ongoing nurse support in patients with Chronic Obstructive Pulmonary Disease (COPD) and comorbidities: the COPE-III study protocol.

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,564 Previous Clinical Trials
570,152 Total Patients Enrolled
50 Trials studying Asthma
21,432 Patients Enrolled for Asthma
Clinical TrialsStudy DirectorGenetech
2,228 Previous Clinical Trials
896,165 Total Patients Enrolled
20 Trials studying Asthma
6,277 Patients Enrolled for Asthma

Media Library

GDC-6599 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05660850 — Phase 2
Asthma Research Study Groups: Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease with Chronic Bronchitis, Part A: CRC Asthma atopic, Part A: CRC Asthma non-atopic, Part A: Unexplained Chronic Cough, Part B: Chronic Refractory Cough with Chronic Obstructive Pulmonary Disease
Asthma Clinical Trial 2023: GDC-6599 Highlights & Side Effects. Trial Name: NCT05660850 — Phase 2
GDC-6599 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05660850 — Phase 2
~30 spots leftby Dec 2025